These data suggest that AKT activation is not dependent on HER2 kinase activation in most urothelial cancer cells, including at least a subset of those with ERBB2 mutation, which contrasts with prior studies suggesting that breast cancers with HER2 amplification are selectively dependent on AKT signaling36. Here, ERBB2 is linked to breast cancer.